Stock Quote

ACOR (Common Stock )
ExchangeNASDAQ (US Dollar)
Price$32.67
Change (%) Stock is Up 0.44 (1.37%)
Volume269,290
Data as of 05/24/13 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

2013 Press Releases

    Webcast ImageWebcast
    Acorda Therapeutics, Inc. at UBS Global Healthcare Conference  (Replay)
    05/22/13 at 10:30 a.m. ET
    Acorda Therapeutics, Inc. at UBS Global Healthcare Conference
    Wednesday, May 22, 2013 10:30 a.m. ET  
    Webcast PresentationHelp Help
    Click here for webcast
    Add to CalendarHelp Help
    Add to Calendar Click here to add this event to your calendar
    Keyword Search
     
    2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
    DateTitle 
    05/21/13Acorda Therapeutics Announces Publication of New Data on Impact of Mobility Impairment Due to Multiple SclerosisPrinter Friendly Version
    05/20/13Acorda Therapeutics Announces Issuance of Additional U.S. Patent for AMPYRA® Covering a Range of Dosage StrengthsPrinter Friendly Version
    05/17/13Acorda Therapeutics’ Legal Department Recognized on Best Legal Departments List by Corporate Counsel MagazinePrinter Friendly Version
    05/15/13Acorda Therapeutics to Present at the UBS Global Healthcare ConferencePrinter Friendly Version
    05/09/13Acorda Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care ConferencePrinter Friendly Version
    05/09/13Acorda Therapeutics Announces Data Showing Dalfampridine Improves Motor Function in Preclinical Model of Post-Stroke Deficits Published in StrokePrinter Friendly Version
    05/06/13Acorda Therapeutics Recognized as One of the Best Places to Work in New York State for Third Consecutive YearPrinter Friendly Version
    05/02/13Acorda Therapeutics Reports First Quarter 2013 Financial ResultsPrinter Friendly Version
    04/25/13Acorda Therapeutics to Host Conference Call to Discuss First Quarter 2013 Financial Results on May 2, 2013Printer Friendly Version
    04/23/13Mayo Clinic and Acorda Therapeutics Announce Initiation of Phase 1 Trial of Remyelinating Antibody in People with Multiple SclerosisPrinter Friendly Version
    04/15/13Acorda Therapeutics Announces Positive AMPYRA® (dalfampridine) Phase 2 Data in People with Post-Stroke DeficitsPrinter Friendly Version
    03/20/13Diazepam Nasal Spray Demonstrates Comparable Bioavailability to Diazepam Rectal Gel in Pharmacokinetic StudyPrinter Friendly Version
    03/13/13Acorda to Present New Research on Novel Multiple Sclerosis and Epilepsy Therapies at American Academy of Neurology 65th Annual MeetingPrinter Friendly Version
    03/07/13Data from First Clinical Trial of GGF2 in Heart Failure Presented at the American College of Cardiology 62nd Annual Scientific SessionPrinter Friendly Version
    02/25/13Acorda Therapeutics to Present at the Cowen & Company 33rd Annual Health Care ConferencePrinter Friendly Version
    02/19/13Acorda Therapeutics to Present at RBC Capital Markets and Citi 2013 Global Healthcare ConferencesPrinter Friendly Version
    02/14/13Acorda Therapeutics Announces Company Intranet Named One of Ten Best in the WorldPrinter Friendly Version
    02/13/13Acorda Therapeutics Reports Fourth Quarter and Full Year 2012 Financial ResultsPrinter Friendly Version
    02/07/13Acorda Therapeutics Presents GGF2 Preclinical Stroke Data at International Stroke ConferencePrinter Friendly Version
    02/07/13Acorda Therapeutics to Present at Leerink Swann Global Healthcare ConferencePrinter Friendly Version
    02/06/13Acorda Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2012 Financial Results on February 13, 2013Printer Friendly Version
    01/24/13Acorda Therapeutics Announces Department of Defense Contract to Support Study of AC105 in Acute Spinal Cord InjuryPrinter Friendly Version
    01/07/13Acorda Therapeutics Provides Corporate Update at 31st Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version

    Other Resources